Research in Down syndrome Associated Alzheimer’s disease: What do we know and where are we going?

In this webinar, Dr. Hendrix will discuss this important milestone in Alzheimer’s disease research and what this decision might mean for people with Down syndrome. He will also discuss other recent research progress in Down syndrome associated Alzheimer’s disease (DS-AD). This presentation will include updates on the LIFE-DSR study sponsored by LuMind IDSC, progress in the development of new Alzheimer’s biomarkers including brain imaging and blood tests. This webinar is timely following the announcement by the FDA on the approval of Aduhelm. Aduhelm (aducanumab) is the first new drug approved by the FDA for Alzheimer’s disease in the general population since 2003 and is the first to attack what is believed to be one of the causes of Alzheimer’s disease, amyloid beta plaques in the brain. Previously-approved drugs only treat the dementia symptoms associated with Alzheimer’s disease but not the underlying disease processes.